Drug Patents Expiring in 2034
1. List of Abilify Maintena Kit drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10525057 | OTSUKA PHARM CO LTD | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function |
Mar, 2034
(10 years from now) | |
Drugs and Companies using ARIPIPRAZOLE ingredient
Market Authorisation Date: 28 February, 2013
Treatment: Maintenance monotherapy treatment of bipolar 1 disorder; Treatment of schizophrenia, with efficacy in treating acute episodes of schizophrenia; Treatment of schizophrenia
Dosage: FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
ABILIFY MAINTENA KIT family patents
6
United States
2. List of Abraxane drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9511046 | BRISTOL MYERS SQUIBB CO | Methods of treating pancreatic cancer |
Jan, 2034
(10 years from now) | |
|
US9511046 (Pediatric) | BRISTOL MYERS SQUIBB CO | Methods of treating pancreatic cancer |
Jul, 2034
(11 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Pediatric Exclusivity (PED) | Jun 6, 2023 |
Drugs and Companies using PACLITAXEL ingredient
Market Authorisation Date: 07 January, 2005
Treatment: Treatment of pancreatic cancer
Dosage: POWDER;INTRAVENOUS
ABRAXANE family patents
6
United States
3
Japan
2
New Zealand
2
China
1
Australia
1
Israel
1
Croatia
1
Korea, Republic of
1
Canada
1
Denmark
1
Spain
1
Portugal
1
Poland
1
Hong Kong
1
Slovenia
1
Mexico
1
RS
1
Brazil
1
South Africa
1
Hungary
1
Lithuania
1
European Union
3. List of Adempas drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10662188 | BAYER HLTHCARE | Forms of methyl {4,6-diamino-2-[1 (2-fluorobenzyl)-1H-pyrazolo[3-4-b]pyridino-3-yl]pyrimidino-5-yl} methyl carbamate |
Feb, 2034
(10 years from now) | |
| US11203593 | BAYER HLTHCARE | Forms of methyl {4,6-diamino-2-[1(2-fluorobenzyl)-1H-pyrazolo[3-4-b]pyridino-3-yl]pyrimidino-5-yl}methyl carbamate |
Feb, 2034
(10 years from now) | |
Drugs and Companies using RIOCIGUAT ingredient
Market Authorisation Date: 08 October, 2013
Treatment: Treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (cteph), (who group 4) after surgical treatment, or inoperable cteph, to improve exercise capacity and who f...
Dosage: TABLET;ORAL
ADEMPAS family patents
6
United States
3
Canada
3
European Union
1
Australia
1
EA
1
Dominican Republic
1
Korea, Republic of
1
Tunisia
1
Peru
1
Costa Rica
1
Nicaragua
1
Chile
1
Singapore
1
Philippines
1
Japan
1
Morocco
1
Hong Kong
1
Mexico
1
Cuba
1
China
1
Brazil
4. List of Airduo Digihaler drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9415008 | TEVA PHARM | Dry powder inhaler |
Oct, 2034
(11 years from now) | |
| US9066957 | TEVA PHARM | Dry powder inhaler |
Oct, 2034
(11 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| M (M) | Jul 9, 2024 |
| Pediatric Exclusivity (PED) | Jan 9, 2025 |
Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient
Market Authorisation Date: 27 January, 2017
Treatment: Treatment of asthma
Dosage: POWDER;INHALATION
AIRDUO DIGIHALER family patents
9
United States
3
Australia
3
Hong Kong
2
EA
2
Korea, Republic of
2
Canada
2
Peru
2
Chile
2
Japan
2
Mexico
2
Argentina
2
China
2
Taiwan
2
European Union
1
Colombia
1
Israel
1
New Zealand
1
Denmark
1
Spain
1
Portugal
1
Philippines
1
Poland
1
Morocco
1
Brazil
1
South Africa
1
Hungary
5. List of Alkindi Sprinkle drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9649280 | ETON | Composition comprising hydrocortisone |
May, 2034
(10 years from now) | |
Drugs and Companies using HYDROCORTISONE ingredient
Market Authorisation Date: 29 September, 2020
Treatment: Treatment of adrenal insufficiency
Dosage: GRANULE;ORAL
ALKINDI SPRINKLE family patents
3
United Kingdom
1
Australia
1
Israel
1
Croatia
1
Korea, Republic of
1
Canada
1
New Zealand
1
Denmark
1
Spain
1
Portugal
1
Russia
1
Poland
1
Japan
1
Hong Kong
1
Slovenia
1
Mexico
1
RS
1
China
1
South Africa
1
Brazil
1
Hungary
1
United States
1
Lithuania
1
European Union
6. List of Alunbrig drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9611283 | TAKEDA PHARMS USA | Methods for inhibiting cell proliferation in ALK-driven cancers |
Apr, 2034
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | May 22, 2027 |
| New Indication (I) | May 22, 2023 |
Drugs and Companies using BRIGATINIB ingredient
Market Authorisation Date: 28 April, 2017
Treatment: Treatment of anaplastic lymphoma kinase (alk)-positive metastatic non-small cell lung cancer (nsclc)
Dosage: TABLET;ORAL
7. List of Arikayce Kit drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9566234 | INSMED INC | Systems for treating pulmonary infections |
Jan, 2034
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Sep 28, 2025 |
| Generating Antibiotic Incentives Now (GAIN) | Sep 28, 2030 |
Drugs and Companies using AMIKACIN SULFATE ingredient
Market Authorisation Date: 28 September, 2018
Treatment: Treating mycobacterium avium complex (mac) lung disease in adults as part of a combination antibacterial drug regimen
Dosage: SUSPENSION, LIPOSOMAL;INHALATION
ARIKAYCE KIT family patents
10
United States
5
Japan
4
Australia
2
Korea, Republic of
2
New Zealand
2
China
2
European Union
1
Colombia
1
Israel
1
Croatia
1
Canada
1
Denmark
1
Spain
1
Portugal
1
Russia
1
Poland
1
Hong Kong
1
Slovenia
1
Mexico
1
Brazil
1
Lithuania
8. List of Aubagio drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9186346 | SANOFI AVENTIS US | Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients |
Feb, 2034
(10 years from now) | |
|
US9186346 (Pediatric) | SANOFI AVENTIS US | Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients |
Aug, 2034
(11 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| M (M) | Apr 30, 2024 |
| Pediatric Exclusivity (PED) | Oct 30, 2024 |
Drugs and Companies using TERIFLUNOMIDE ingredient
Market Authorisation Date: 12 September, 2012
Treatment: Treatment of patients with relapsing forms of multiple sclerosis while managing the risk of teriflunomide and rosuvastatin interaction by limiting the rosuvastatin dose to no more than 10mg and/or adm...
Dosage: TABLET;ORAL
AUBAGIO family patents
4
United States
1
European Union
9. List of Austedo drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US9814708 (Pediatric) | TEVA BRANDED PHARM | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Mar, 2034
(10 years from now) | |
|
US9296739 (Pediatric) | TEVA BRANDED PHARM | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Mar, 2034
(10 years from now) | |
|
US9233959 (Pediatric) | TEVA BRANDED PHARM | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Mar, 2034
(10 years from now) | |
|
US9550780 (Pediatric) | TEVA BRANDED PHARM | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Mar, 2034
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Apr 3, 2024 |
| M (M) | Jun 24, 2024 |
| Pediatric Exclusivity (PED) | Oct 3, 2024 |
Drugs and Companies using DEUTETRABENAZINE ingredient
Market Authorisation Date: 03 April, 2017
Treatment: NA
Dosage: TABLET;ORAL
10. List of Auvelity drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11517542 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US10933034 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US10251879 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US10092561 | AXSOME | Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan |
Nov, 2034
(11 years from now) | |
| US10894046 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US11191739 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US10874664 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US10080727 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
| US11197839 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US11147808 | AXSOME | Method of decreasing the fluctuation index of dextromethorphan |
Nov, 2034
(11 years from now) | |
| US11207281 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US11141416 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US11141388 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US11213521 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US11129826 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US11123343 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US10966974 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US10512643 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
| US10105361 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
| US10105327 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphane and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
| US10092560 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
| US9968568 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
| US11510918 | AXSOME | NA |
Nov, 2034
(11 years from now) | |
| US11478468 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US11497721 | AXSOME | NA |
Nov, 2034
(11 years from now) | |
| US11524008 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US11524007 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US11517543 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US10463634 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
| US11541048 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US11541021 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US11534414 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US11617747 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US11617728 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US11596627 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US11382874 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US11364233 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US9457025 | AXSOME | Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan |
Nov, 2034
(11 years from now) | |
| US10058518 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US9278095 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US9867819 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
| US9168234 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US9861595 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
| US9700553 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
| US11357744 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US11344544 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US9486450 | AXSOME | Hydroxybupropion and related compounds as modulators of drug plasma levels |
Nov, 2034
(11 years from now) | |
| US9474731 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
| US9375429 | AXSOME | Compositions and methods comprising erythrohydroxybupropion and related compounds for improving the efficacy of dextromethorphan |
Nov, 2034
(11 years from now) | |
| US9421176 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
| US9408815 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US9763932 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
| US11311534 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US9205083 | AXSOME | Compositions and methods comprising erythrohydroxybupropion and related compounds for improving the efficacy of dextromethorphan |
Nov, 2034
(11 years from now) | |
| US9707191 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
| US10898453 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US11433067 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US9700528 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
| US9370513 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
| US9457023 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
| US9238032 | AXSOME | Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan |
Nov, 2034
(11 years from now) | |
| US11096937 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US11298352 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US10966941 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US11298351 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US11090300 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US10894047 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US10064857 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US11291665 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US11291638 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US10786469 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
| US11253492 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US10881657 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US10874663 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US10799497 | AXSOME | Combination of dextromethorphan and bupropion for treating depression |
Nov, 2034
(11 years from now) | |
| US11058648 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US11273133 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US10864209 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US10806710 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US10881624 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
| US10786496 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
| US11020389 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US11185515 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US10945973 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US11285146 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US11285118 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US10596167 | AXSOME | Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan |
Nov, 2034
(11 years from now) | |
| US11439636 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US9314462 | AXSOME | Compositions and methods for increasing dextromethorphan plasma levels and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
| US9198905 | AXSOME | Compositions and methods for reducing dextrorphan plasma levels and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
| US11426401 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US11426370 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US11419867 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US10772850 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US11273134 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US11253491 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US11234946 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US10548857 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
| US11229640 | AXSOME | Combination of dextromethorphan and bupropion for treating depression |
Nov, 2034
(11 years from now) | |
| US10874665 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
| US10780066 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Product (NP) | Aug 18, 2025 |
Drugs and Companies using BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE ingredient
Market Authorisation Date: 18 August, 2022
Treatment: Dextromethorphan and bupropion in combination to treat major depressive disorder; Dextromethorphan and bupropion in combination to increase dextromethorphan plasma levels
Dosage: TABLET, EXTENDED RELEASE;ORAL
AUVELITY family patents
198
United States
15
China
12
Australia
11
Korea, Republic of
10
Japan
9
Canada
9
European Union
8
Israel
8
New Zealand
8
Singapore
3
Ecuador
3
Peru
3
Costa Rica
3
Mexico
3
Brazil
2
Colombia
2
Malaysia
2
Chile
1
Croatia
1
Denmark
1
Spain
1
Nicaragua
1
Portugal
1
Poland
1
Morocco
1
Hong Kong
1
Slovenia
1
RS
1
Hungary
1
Lithuania
11. List of Ayvakit drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9994575 | BLUEPRINT MEDICINES | Compositions useful for treating disorders related to kit |
Oct, 2034
(11 years from now) | |
| US9944651 | BLUEPRINT MEDICINES | Compositions useful for treating disorders related to kit |
Oct, 2034
(11 years from now) | |
| US9200002 | BLUEPRINT MEDICINES | Compositions useful for treating disorders related to KIT |
Oct, 2034
(11 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jan 9, 2025 |
| New Indication (I) | Jun 16, 2024 |
| Orphan Drug Exclusivity (ODE) | Jan 9, 2027 |
Drugs and Companies using AVAPRITINIB ingredient
NCE-1 date: 2024-01-10
Market Authorisation Date: 09 January, 2020
Treatment: Treatment of unresectable or metastatic gastrointestinal stromal tumor (gist) harboring a platelet-derived growth factor receptor alpha (pdgfra) exon 18 mutation; Treatment of advanced systemic mastoc...
Dosage: TABLET;ORAL
AYVAKIT family patents
9
United States
3
Hungary
2
Spain
2
Portugal
2
Poland
2
Japan
2
China
2
Lithuania
2
European Union
1
Australia
1
Israel
1
Croatia
1
Korea, Republic of
1
Canada
1
Netherlands
1
New Zealand
1
Denmark
1
Uruguay
1
Cyprus
1
Singapore
1
Philippines
1
Russia
1
Norway
1
Hong Kong
1
Slovenia
1
Mexico
1
Argentina
1
Brazil
1
RS
1
South Africa
1
Taiwan
12. List of Barhemsys drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9084765 | ACACIA | Use of amisulpride as an anti-emetic |
Feb, 2034
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Feb 26, 2025 |
Drugs and Companies using AMISULPRIDE ingredient
NCE-1 date: 2024-02-27
Market Authorisation Date: 26 February, 2020
Treatment: Prevention of post-operative nausea and vomiting; Treatment of post-operative nausea and vomiting
Dosage: SOLUTION;INTRAVENOUS
BARHEMSYS family patents
10
United States
3
Croatia
3
Denmark
3
Spain
3
Cyprus
3
Portugal
3
Poland
3
Slovenia
3
Mexico
3
RS
3
European Union
2
Japan
2
United Kingdom
2
San Marino
1
Australia
1
EA
1
Israel
1
Korea, Republic of
1
Canada
1
New Zealand
1
Norway
1
Hong Kong
1
Brazil
1
China
1
Hungary
1
Lithuania
13. List of Bosulif drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11103497 | PF PRISM CV | Treatment of imatinib resistant leukemia |
Feb, 2034
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Dec 19, 2024 |
Drugs and Companies using BOSUTINIB MONOHYDRATE ingredient
Market Authorisation Date: 04 September, 2012
Treatment: A method for treating a bcrabl positive leukemia in a subject that is resistant to imatinib comprising administering to the subject a therapeutically effective amount of bosutinib, wherein the subject...
Dosage: TABLET;ORAL
BOSULIF family patents
4
European Union
3
Canada
3
Japan
3
United States
2
Denmark
2
Spain
2
Portugal
2
Poland
2
Slovenia
1
Panama
1
Australia
1
Korea, Republic of
1
Chile
1
Cyprus
1
Russia
1
Hong Kong
1
Mexico
1
Brazil
1
China
1
South Africa
1
Hungary
1
Taiwan
14. List of Brukinsa drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9447106 | BEIGENE | Substituted pyrazolo[1,5-a]pyrimidines as bruton's tyrosine kinase modulators |
Apr, 2034
(10 years from now) | |
| US11142528 | BEIGENE | Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators |
Apr, 2034
(10 years from now) | |
| US10570139 | BEIGENE | Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators |
Apr, 2034
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Nov 14, 2024 |
| Orphan Drug Exclusivity (ODE) | Sep 14, 2028 |
| New Indication (I) | Sep 14, 2024 |
Drugs and Companies using ZANUBRUTINIB ingredient
NCE-1 date: 2023-11-15
Market Authorisation Date: 14 November, 2019
Treatment: Treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy; For the treatment of patients with waldenstrom's macroglobulinemia; Relapsed or refractory marginal ...
Dosage: CAPSULE;ORAL
BRUKINSA family patents
5
United States
3
China
2
Hungary
2
Lithuania
1
Australia
1
EA
1
Croatia
1
Korea, Republic of
1
Canada
1
Netherlands
1
New Zealand
1
Denmark
1
Spain
1
Cyprus
1
Singapore
1
Portugal
1
Poland
1
Japan
1
Hong Kong
1
Slovenia
1
Mexico
1
RS
1
Brazil
1
South Africa
1
European Union
15. List of Camzyos drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9181200 | BRISTOL | Pyrimidinedione compounds |
Jun, 2034
(11 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9585883 | BRISTOL | Pyrimidinedione compounds |
Jun, 2034
(11 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Apr 28, 2029 |
| New Chemical Entity Exclusivity (NCE) | Apr 28, 2027 |
Drugs and Companies using MAVACAMTEN ingredient
NCE-1 date: 2026-04-28
Market Authorisation Date: 28 April, 2022
Treatment: Treatment of adults with symptomatic new york heart association (nyha) class ii-iii obstructive hypertrophic cardiomyopathy (hcm) to improve functional capacity and symptoms
Dosage: CAPSULE;ORAL
CAMZYOS family patents
12
United States
4
Australia
3
Israel
3
Korea, Republic of
3
Japan
2
EA
2
Singapore
2
China
2
European Union
1
Croatia
1
Dominican Republic
1
Canada
1
New Zealand
1
Denmark
1
Spain
1
Tunisia
1
Peru
1
Malaysia
1
Costa Rica
1
Chile
1
Portugal
1
Ukraine
1
Philippines
1
Poland
1
Morocco
1
Hong Kong
1
Slovenia
1
Guatemala
1
Mexico
1
Brazil
1
South Africa
1
RS
1
Hungary
1
Lithuania
16. List of Caplyta drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11026951 | INTRA-CELLULAR | Methods of treating bipolar disorder |
Dec, 2034
(11 years from now) | |
| US9956227 | INTRA-CELLULAR | Method for the treatment of residual symptoms of schizophrenia |
Dec, 2034
(11 years from now) | |
| US10960009 | INTRA-CELLULAR | Methods of treating schizophrenia and depression |
Dec, 2034
(11 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Dec 20, 2024 |
| New Indication (I) | Dec 17, 2024 |
Drugs and Companies using LUMATEPERONE TOSYLATE ingredient
NCE-1 date: 2023-12-21
Market Authorisation Date: 20 December, 2019
Treatment: Treatment of bipolar i disorder, bipolar ii disorder, or bipolar depression; Treatment of schizophrenia with improvement in residual symptoms of schizophrenia; Treatment of schizophrenia
Dosage: CAPSULE;ORAL
CAPLYTA family patents
12
United States
5
Korea, Republic of
4
Australia
3
Canada
3
Japan
2
China
2
Israel
2
European Union
1
Mexico
1
Denmark
1
Portugal
1
Hungary
1
Spain
1
Russia
1
Poland
17. List of Cibinqo drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9035074 | PFIZER | Pyrrolo[2,3-D]pyrimidine derivatives |
Feb, 2034
(10 years from now) | |
| US9545405 | PFIZER | Pyrrolo[2,3-D]pyrimidine derivatives |
Feb, 2034
(10 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9549929 | PFIZER | Pyrrolo[2,3-D]pyrimidine derivatives |
Feb, 2034
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jan 14, 2027 |
| New Patient Population (NPP) | Feb 9, 2026 |
Drugs and Companies using ABROCITINIB ingredient
NCE-1 date: 2026-01-14
Market Authorisation Date: 14 January, 2022
Treatment: Treatment of adults with refractory, moderate-to-severe atopic dermatitis not adequately controlled with other systemic drug products or when use of those therapies is inadvisable
Dosage: TABLET;ORAL
CIBINQO family patents
4
United States
3
Hungary
3
Lithuania
2
Croatia
2
Denmark
2
Spain
2
ME
2
Cyprus
2
Portugal
2
Poland
2
Japan
2
Slovenia
2
RS
2
China
2
European Union
1
Australia
1
EA
1
Israel
1
IB
1
Dominican Republic
1
Korea, Republic of
1
Moldova, Republic of
1
Canada
1
Netherlands
1
New Zealand
1
Tunisia
1
Uruguay
1
Peru
1
Malaysia
1
Costa Rica
1
Chile
1
Singapore
1
Ukraine
1
Philippines
1
Morocco
1
Norway
1
Hong Kong
1
Mexico
1
Georgia
1
Argentina
1
South Africa
1
Cuba
1
Brazil
1
Turkey
1
Taiwan
18. List of Clenpiq drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10624879 | FERRING PHARMS INC | Liquid pharmaceutical composition |
Jun, 2034
(11 years from now) | |
| US11191753 | FERRING PHARMS INC | Liquid pharmaceutical composition |
Jun, 2034
(11 years from now) | |
| US9827231 | FERRING PHARMS INC | Liquid pharmaceutical composition |
Jun, 2034
(11 years from now) | |
Drugs and Companies using CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE ingredient
Market Authorisation Date: 28 November, 2017
Treatment: For cleansing of the colon as a preparation for colonoscopy; For cleansing the large intestine as a preparation for colonoscopy
Dosage: SOLUTION;ORAL
CLENPIQ family patents
4
United States
2
Korea, Republic of
1
Canada
1
Mexico
1
China
1
Australia
1
Russia
1
Spain
1
Japan
1
European Union
19. List of Contrave drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10231964 | NALPROPION | Compositions and methods for weight loss in at risk patient populations |
Jul, 2034
(11 years from now) | |
| US10835527 | NALPROPION | Compositions and methods for reducing major adverse cardiovascular events |
Jul, 2034
(11 years from now) | |
| US10828294 | NALPROPION | Compositions and methods for weight loss in at risk patient populations |
Jul, 2034
(11 years from now) | |
Drugs and Companies using BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 10 September, 2014
Treatment: For chronic weight management for treating overweight or obesity
Dosage: TABLET, EXTENDED RELEASE;ORAL
CONTRAVE family patents
16
United States
2
Korea, Republic of
2
Japan
2
Argentina
2
China
2
European Union
1
Ecuador
1
Australia
1
EA
1
Israel
1
Croatia
1
Canada
1
New Zealand
1
Denmark
1
Spain
1
Tunisia
1
Uruguay
1
Peru
1
Costa Rica
1
Chile
1
Singapore
1
Portugal
1
Russia
1
Poland
1
Morocco
1
Slovenia
1
Mexico
1
RS
1
Hungary
1
Taiwan
1
Lithuania
20. List of Cosela drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10085992 | G1 THERAP | Transient protection of normal cells during chemotherapy |
Mar, 2034
(10 years from now) | |
| US10966984 | G1 THERAP | Transient protection of normal cells during chemotherapy |
Mar, 2034
(10 years from now) | |
| US11040042 | G1 THERAP | Transient protection of normal cells during chemotherapy |
Mar, 2034
(10 years from now) | |
| US9487530 | G1 THERAP | Transient protection of normal cells during chemotherapy |
Mar, 2034
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Feb 12, 2026 |
Drugs and Companies using TRILACICLIB DIHYDROCHLORIDE ingredient
NCE-1 date: 2025-02-12
Market Authorisation Date: 12 February, 2021
Treatment: A method to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a carboplatin and etoposide-containing regimen for extensive-stage small cell l...
Dosage: POWDER;INTRAVENOUS
COSELA family patents
26
United States
10
Japan
6
China
4
Canada
4
Hong Kong
4
European Union
1
Slovenia
1
Cyprus
1
RS
1
ME
1
Denmark
1
Hungary
1
Portugal
1
Spain
1
Poland
1
Croatia
1
Lithuania
21. List of Cotellic drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11087354 | GENENTECH INC | Combination therapies |
Jun, 2034
(11 years from now) | |
|
US11087354 (Pediatric) | GENENTECH INC | Combination therapies |
Dec, 2034
(11 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Indication (I) | Oct 28, 2025 |
| M (M) | Jul 28, 2025 |
| Orphan Drug Exclusivity (ODE) | Oct 28, 2029 |
| Pediatric Exclusivity (PED) | Jan 28, 2026 |
Drugs and Companies using COBIMETINIB FUMARATE ingredient
Market Authorisation Date: 10 November, 2015
Treatment: Method of using cobimetinib for the treatment of melanoma
Dosage: TABLET;ORAL
COTELLIC family patents
7
United States
5
Korea, Republic of
3
New Zealand
3
Singapore
2
Canada
2
Japan
2
China
2
European Union
1
Colombia
1
Australia
1
EA
1
Israel
1
Croatia
1
Denmark
1
Spain
1
Peru
1
Malaysia
1
Costa Rica
1
Chile
1
Portugal
1
Ukraine
1
Philippines
1
Poland
1
Morocco
1
Hong Kong
1
Slovenia
1
Mexico
1
Brazil
1
South Africa
1
RS
1
Hungary
1
Lithuania
22. List of Dexycu Kit drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10159683 | EYEPOINT PHARMS | Use of sustained release dexamethasone in post-cataract surgery inflammation |
May, 2034
(10 years from now) | |
| US10028965 | EYEPOINT PHARMS | Use of sustained release dexamethasone in post-cataract surgery inflammation |
May, 2034
(10 years from now) | |
| US10022502 | EYEPOINT PHARMS | Dose guides for injection syringe |
Jun, 2034
(11 years from now) | |
Drugs and Companies using DEXAMETHASONE ingredient
Market Authorisation Date: 09 February, 2018
Treatment: Treatment of postoperative inflammation
Dosage: SUSPENSION;INTRAOCULAR
DEXYCU KIT family patents
13
United States
3
Korea, Republic of
3
China
3
European Union
2
Australia
2
Canada
2
Spain
2
Japan
1
Croatia
1
New Zealand
1
Denmark
1
Portugal
1
Poland
1
Slovenia
1
Mexico
1
Brazil
1
RS
1
Hungary
1
Lithuania
23. List of Dificid drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9808530 | CUBIST PHARMS LLC | Composition of tiacumicin compounds |
May, 2034
(10 years from now) | |
|
US9808530 (Pediatric) | CUBIST PHARMS LLC | Composition of tiacumicin compounds |
Nov, 2034
(11 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Product (NP) | Jan 24, 2023 |
| Orphan Drug Exclusivity (ODE) | Jan 24, 2027 |
| Pediatric Exclusivity (PED) | Jul 24, 2023 |
Drugs and Companies using FIDAXOMICIN ingredient
Market Authorisation Date: 24 January, 2020
Treatment: NA
Dosage: FOR SUSPENSION;ORAL
DIFICID family patents
3
European Union
1
Australia
1
EA
1
Croatia
1
Korea, Republic of
1
Moldova, Republic of
1
Canada
1
New Zealand
1
Denmark
1
Spain
1
Cyprus
1
Jordan
1
Portugal
1
Ukraine
1
Poland
1
Japan
1
Slovenia
1
Georgia
1
Argentina
1
RS
1
China
1
South Africa
1
Hungary
1
United States
1
Taiwan
1
Lithuania
24. List of Dilaudid drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9248229 | FRESENIUS KABI USA | Packaging system for oxygen-sensitive drugs |
Mar, 2034
(10 years from now) | |
Drugs and Companies using HYDROMORPHONE HYDROCHLORIDE ingredient
Market Authorisation Date: 11 January, 1984
Treatment: NA
Dosage: INJECTABLE;INJECTION
DILAUDID family patents
6
United States
3
European Union
2
China
2
Australia
1
Canada
1
Brazil
1
Denmark
1
Portugal
1
Spain
1
Japan
1
Hong Kong
25. List of Doryx drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9511031 | MAYNE PHARMA | Controlled release doxycycline |
Oct, 2034
(11 years from now) | |
| US9295652 | MAYNE PHARMA | Controlled release doxycycline |
Oct, 2034
(11 years from now) | |
| US9446057 | MAYNE PHARMA | Controlled release doxycycline |
Dec, 2034
(11 years from now) | |
Drugs and Companies using DOXYCYCLINE HYCLATE ingredient
Market Authorisation Date: 06 May, 2005
Treatment: To treat or prevent infections caused by susceptible bacteria using delayed-release tablets consisting of doxycycline hyclate coated pellets in a tablet
Dosage: TABLET, DELAYED RELEASE;ORAL
DORYX family patents
7
United States
26. List of Durysta drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9492316 | ALLERGAN INC | Prostamide-containing intraocular implants and methods of use thereof |
Oct, 2034
(11 years from now) | |
| US9980974 | ALLERGAN INC | Prostamide-containing intraocular implants and methods of use thereof |
Oct, 2034
(11 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Product (NP) | Mar 4, 2023 |
Drugs and Companies using BIMATOPROST ingredient
Market Authorisation Date: 04 March, 2020
Treatment: Reduction of intraocular pressure (iop) in patients with open angle glaucoma(oag) or ocular hypertension (oht) with a biodegradable bimatoprost implant
Dosage: IMPLANT;OPHTHALMIC
DURYSTA family patents
7
United States
4
European Union
3
Australia
2
Israel
2
Denmark
2
Spain
2
Singapore
2
Portugal
2
Poland
2
Japan
2
Slovenia
2
Mexico
2
China
2
Hungary
1
Korea, Republic of
1
Canada
1
New Zealand
1
Saudi Arabia
1
Chile
1
Cyprus
1
Ukraine
1
Philippines
1
Russia
1
Norway
1
Hong Kong
1
South Africa
1
Turkey
27. List of Epclusa drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10086011 | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jan, 2034
(10 years from now) | |
| US9757406 | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jan, 2034
(10 years from now) | |
| US11116783 | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jan, 2034
(10 years from now) | |
|
US9757406 (Pediatric) | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jul, 2034
(11 years from now) | |
|
US10086011 (Pediatric) | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jul, 2034
(11 years from now) | |
|
US11116783 (Pediatric) | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jul, 2034
(11 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Jun 10, 2028 |
| New Strength (NS) | Mar 19, 2023 |
| M (M) | Apr 27, 2025 |
| New Patient Population (NPP) | Mar 19, 2023 |
| Pediatric Exclusivity (PED) | May 15, 2023 |
Drugs and Companies using SOFOSBUVIR; VELPATASVIR ingredient
Market Authorisation Date: 28 June, 2016
Treatment: For the treatment of hepatitis c
Dosage: TABLET;ORAL
EPCLUSA family patents
11
United States
3
Australia
3
European Union
2
Spain
2
Portugal
2
Poland
2
Japan
2
Hong Kong
2
Slovenia
1
EA
1
Korea, Republic of
1
Canada
1
New Zealand
1
Uruguay
1
Singapore
1
Mexico
1
Argentina
1
China
1
Taiwan
28. List of Epinephrine drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10039728 | BELCHER | More potent and less toxic formulations of epinephrine and methods of medical use |
Aug, 2034
(11 years from now) | |
| US10004700 | BELCHER | More potent and less toxic formulations of epinephrine and methods of medical use |
Aug, 2034
(11 years from now) | |
| US9283197 | BELCHER | More potent and less toxic formulations of epinephrine and methods of medical use |
Aug, 2034
(11 years from now) | |
Drugs and Companies using EPINEPHRINE ingredient
Market Authorisation Date: 29 July, 2014
Treatment: Increasing mean arterial blood pressure in adult patients with hypotension associated with septic shock; Emergency treatment of allergic reactions (type 1), including anaphylaxis; A method of treating...
Dosage: SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS; SOLUTION;INTRAVENOUS, INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS
29. List of Evomela drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10040872 | ACROTECH | Alkylated cyclodextrin compositions and processes for preparing and using the same |
Jan, 2034
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Mar 10, 2023 |
Drugs and Companies using MELPHALAN HYDROCHLORIDE ingredient
Market Authorisation Date: 10 March, 2016
Treatment: NA
Dosage: POWDER;INTRAVENOUS
EVOMELA family patents
6
United States
2
EA
2
Chile
2
Japan
2
Hong Kong
2
South Africa
1
Australia
1
Israel
1
Korea, Republic of
1
Canada
1
New Zealand
1
Malaysia
1
Singapore
1
Ukraine
1
Philippines
1
Mexico
1
Brazil
1
China
1
European Union
30. List of Evzio drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9517307 | KALEO INC | Devices and methods for delivering opioid antagonists including formulations for naloxone |
Jul, 2034
(11 years from now) | |
Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 03 April, 2014
Treatment: Use of an auto injector to administer naloxone hcl
Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS
EVZIO family patents
2
United States
31. List of Evzio (autoinjector) drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9517307 | KALEO INC | Devices and methods for delivering opioid antagonists including formulations for naloxone |
Jul, 2034
(11 years from now) | |
Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 19 October, 2016
Treatment: Use of an auto injector to administer naloxone hcl
Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS
EVZIO (AUTOINJECTOR) family patents
2
United States
32. List of Exondys 51 drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9506058 | SAREPTA THERAPS INC | Compositions for treating muscular dystrophy |
Mar, 2034
(10 years from now) | |
| US10364431 | SAREPTA THERAPS INC | Compositions for treating muscular dystrophy |
Mar, 2034
(10 years from now) | |
| US10337003 | SAREPTA THERAPS INC | Compositions for treating muscular dystrophy |
Mar, 2034
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Sep 19, 2023 |
Drugs and Companies using ETEPLIRSEN ingredient
Market Authorisation Date: 19 September, 2016
Treatment: Treatment of duchenne muscular dystrophy in patients having a mutation of the dmd gene that is amenable to exon 51 skipping; Restoring an mrna reading frame to induce dystrophin protein production in ...
Dosage: SOLUTION;INTRAVENOUS
EXONDYS 51 family patents
11
United States
3
Australia
3
Israel
2
Mexico
2
China
2
New Zealand
2
Japan
2
Korea, Republic of
2
European Union
1
Canada
1
Brazil
1
EA
1
Hong Kong
33. List of Firdapse drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10793893 | CATALYST PHARMS | Methods of administering 3,4-diaminopyridine |
May, 2034
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Nov 28, 2023 |
| Orphan Drug Exclusivity (ODE) | Nov 28, 2025 |
| New Patient Population (NPP) | Sep 29, 2025 |
Drugs and Companies using AMIFAMPRIDINE PHOSPHATE ingredient
NCE-1 date: 2022-11-28
Market Authorisation Date: 28 November, 2018
Treatment: Method of treating lambert-eaton myasthenic syndrome with amifampridine
Dosage: TABLET;ORAL
FIRDAPSE family patents
13
United States
1
Canada
34. List of Fulvestrant drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10188663 | FRESENIUS KABI USA | Fulvestrant formulations |
Feb, 2034
(10 years from now) | |
| US9833459 | FRESENIUS KABI USA | Fulvestrant formulations |
Feb, 2034
(10 years from now) | |
| US9271990 | FRESENIUS KABI USA | Fulvestrant formulations |
May, 2034
(10 years from now) | |
Drugs and Companies using FULVESTRANT ingredient
Market Authorisation Date: 20 May, 2019
Treatment: Treatment of hormone receptor positive advanced breast cancer in postmenopausal women
Dosage: SOLUTION;INTRAMUSCULAR
FULVESTRANT family patents
5
United States
35. List of Furoscix drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11433044 | SCPHARMACEUTICALS | Pharmaceutical formulations for subcutaneous administration of furosemide |
Apr, 2034
(10 years from now) | |
| US9884039 | SCPHARMACEUTICALS | Pharmaceutical formulations for subcutaneous administration of furosemide |
Apr, 2034
(10 years from now) | |
| US10272064 | SCPHARMACEUTICALS | Pharmaceutical formulations for subcutaneous administration of furosemide |
Apr, 2034
(10 years from now) | |
Drugs and Companies using FUROSEMIDE ingredient
Market Authorisation Date: 07 October, 2022
Treatment: Use of a liquid formulation comprising furosemide to treat congestion due to fluid overload (edema) in adults with nyha class ii/iii chronic heart failure
Dosage: SOLUTION;SUBCUTANEOUS
FUROSCIX family patents
6
United States
2
Singapore
2
Japan
2
Korea, Republic of
2
European Union
1
Canada
1
Mexico
1
Brazil
1
China
1
Australia
1
Denmark
1
Israel
1
Portugal
1
Spain
1
Hong Kong
36. List of Ganzyk-rtu drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9486530 | EXELA PHARMA | Ganciclovir compositions and related methods |
Sep, 2034
(11 years from now) | |
Drugs and Companies using GANCICLOVIR ingredient
Market Authorisation Date: 17 February, 2017
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
37. List of Giapreza drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11559559 | LA JOLLA PHARMA | NA |
Dec, 2034
(11 years from now) | |
| US9220745 | LA JOLLA PHARMA | Angiotensin II alone or in combination for the treatment of hypotension |
Dec, 2034
(11 years from now) | |
| US10028995 | LA JOLLA PHARMA | Angiotensin II alone or in combination for the treatment of hypotension |
Dec, 2034
(11 years from now) | |
| US10493124 | LA JOLLA PHARMA | Angiotensin II alone or in combination for the treatment of hypotension |
Dec, 2034
(11 years from now) | |
| US11096983 | LA JOLLA PHARMA | Angiotensin II alone or in combination for the treatment of hypotension |
Dec, 2034
(11 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Dec 21, 2022 |
Drugs and Companies using ANGIOTENSIN II ACETATE ingredient
NCE-1 date: 2021-12-21
Market Authorisation Date: 21 December, 2017
Treatment: Increasing blood pressure in a patient having distributive shock; Maintaining mean arterial pressure of about 65 mmhg or higher with angiotensin ii in shock patients treated with catecholamines and re...
Dosage: SOLUTION;INTRAVENOUS
GIAPREZA family patents
9
United States
3
Japan
3
China
2
Australia
2
EA
2
Korea, Republic of
2
European Union
1
Israel
1
Croatia
1
Canada
1
New Zealand
1
Denmark
1
Spain
1
Cyprus
1
Portugal
1
Poland
1
Slovenia
1
Mexico
1
Brazil
1
RS
1
Hungary
1
Lithuania
38. List of Givlaari drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10119143 | ALNYLAM PHARMS INC | Compositions and methods for inhibiting expression of the ALAS1 gene |
Oct, 2034
(11 years from now) | |
| US11028392 | ALNYLAM PHARMS INC | Compositions and methods for inhibiting expression of the ALAS1 gene |
Oct, 2034
(11 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Nov 20, 2024 |
| Orphan Drug Exclusivity (ODE) | Nov 20, 2026 |
Drugs and Companies using GIVOSIRAN SODIUM ingredient
NCE-1 date: 2023-11-21
Market Authorisation Date: 20 November, 2019
Treatment: Treatment of acute hepatic porphyria
Dosage: SOLUTION;SUBCUTANEOUS